サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1587504

抗菌薬耐性診断の市場規模、シェア、動向分析レポート：技術別、最終用途別、病原体別、地域別、セグメント予測、2025年～2030年

Antimicrobial Resistance Diagnostics Market Size, Share & Trends Analysis Report By Technology (Microbiology Culture, PCR), By End-use (Hospitals, Diagnostic Laboratories), By Pathogen, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 120 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
抗菌薬耐性診断の市場規模、シェア、動向分析レポート：技術別、最終用途別、病原体別、地域別、セグメント予測、2025年～2030年
出版日: 2024年10月15日
発行: Grand View Research
ページ情報: 英文 120 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗菌薬耐性診断市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の抗菌薬耐性診断市場規模は、2025年から2030年にかけてCAGR 6.55%を記録し、2030年までに67億米ドルに達する見込みです。

特にヘルスケア施設における薬剤耐性菌感染症のリスク増大と、AMRの脅威と戦うための政府・非政府機関の取り組みの増加が、市場成長の主な要因です。加えて、抗菌薬耐性を管理するために主要な市場プレーヤーが行っている様々な戦略的イニシアチブも市場拡大に寄与しています。例えば、2021年3月には、バイオメリューとGIZが共同でナイジェリア疾病管理センターを支援し、AMRとの闘いを強化しています。

薬剤耐性細菌感染症に対する迅速検査やPoC検査の採用が増加していることから、予測期間中に市場が拡大すると予想されます。さらに、Danaher社、Abbott社などの大手市場企業は、抗菌薬耐性菌感染症に対する迅速診断検査の強固な製品ポートフォリオを有しています。さらに、AMR Industry Allianceのような非政府機関の関与の増加は、規制機関が抗菌薬耐性を管理するための診断ソリューションの開発を後押しする戦略を立てるのを支援しています。

抗菌薬耐性感染症の診断のための新規かつ自動化された検査ソリューションの開発のための資金調達の増加は、予測期間中の市場成長を促進すると予想されます。例えば、2022年5月、欧州投資銀行は、微生物疾患の完全自動化検査の研究開発のため、POCARED Diagnostics社に2,400万米ドル以上の資金を提供しました。POCARED Diagnosticsは、数時間以内に結果を提供できる新しい微生物検査の開発に携わっています。

抗菌剤耐性は今後数年で増加すると予想されています。したがって、抗菌薬耐性の効果的な管理と進行モニタリングのために、正確で迅速な検査オプションの需要が増加すると予想されます。CDCによると、米国における抗菌薬耐性による直接的な医療費は年間約200億米ドルです。

新興国市場の主なプレーヤーは、市場での地位を強化するために、新規検査の開拓に継続的に取り組んでいます。さらに、買収、提携、協力などの他の戦略も、世界のさまざまな地域で製品ポートフォリオを拡大するために主要企業が採用しています。例えば、2022年8月、Accelerate DiagnosticsとBDは、抗菌剤耐性の脅威と戦うための協業を発表しました。この契約により、BDはAccelerate Diagnosticsの膨大な顧客に抗生物質関連耐性の迅速診断ソリューションを提供します。

抗菌薬耐性診断市場レポートハイライト

  • PCR分野が市場を独占し、2024年には24.19%の最大収益シェアを占めました。PCR技術の進歩は、その高い精度による広範な採用とともに、このセグメントの大きなシェアを牽引する主な要因となっています。
  • 2024年には、メチシリン耐性黄色ブドウ球菌セグメントが28.33%の最大市場シェアを占めました。病院環境におけるMRSAの発生率の上昇が、このセグメント拡大の主な要因です。
  • 2024年には、病院セグメントが市場をリードし、売上シェアの48.07%を占めました。このセグメントの成長の原動力は、院内感染の発生率の上昇、抗菌薬耐性（AMR）感染による入院の増加など、いくつかの要因です。
  • 北米の抗菌薬耐性診断薬市場は、2024年に42.03％の収益シェアで世界市場全体を支配しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗菌薬耐性診断市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 抗菌薬耐性診断市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 抗菌薬耐性診断市場：技術別推定・動向分析

  • セグメントダッシュボード
  • 抗菌薬耐性診断市場：技術変動分析
  • 抗菌薬耐性診断市場：技術展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 微生物学培養
  • 免疫測定
    • PCR
    • 次世代シーズ
    • 質量分析
    • 迅速ポイントオブケア
    • その他

第5章 抗菌薬耐性診断市場：病原体別推定・動向分析

  • セグメントダッシュボード
  • 抗菌薬耐性診断市場：病原体変動分析
  • 病原体別抗菌薬耐性診断市場展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 薬剤耐性肺炎球菌（DRSP）
  • 薬剤耐性カンピロバクター（DRC）
  • クロストリジウム・ディフィシル（CD）
  • 薬剤耐性淋菌（DRNG）
  • 薬剤耐性サルモネラ（DRNTS）
  • その他

第6章 抗菌薬耐性診断市場：最終用途別推定・動向分析

  • セグメントダッシュボード
  • 抗菌薬耐性診断市場：最終用途変動分析
  • 最終用途別抗菌薬耐性診断市場展望
  • 2018年から2030年までの市場規模と予測および動向分析
  • 病院
  • 診断ラボ
  • 製薬・バイオテクノロジー企業
  • その他

第7章 抗菌薬耐性診断市場：地域別推定・動向分析

  • 地域ダッシュボード
  • 市場規模、予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業の分類
  • 主要市場参入企業による最近の動向と影響分析
  • 企業市場シェア分析、2024年
  • 主要企業プロファイル
    • bioMerieux
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • BD
    • Danaher
    • Accelerate Diagnostics, Inc.
    • Molsid
    • Vela Diagnostics
    • Visby Medical, Inc.
    • Hologic, Inc.
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 4 Global Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 5 Global Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 6 North America Antimicrobial Resistance Diagnostics market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 8 North America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 9 North America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 10 U.S Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 11 U.S Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 12 U.S Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 13 Mexico Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 14 Mexico Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 15 Mexico Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 16 Canada Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 17 Canada Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 18 Canada Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 19 Europe Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 21 Europe Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 22 Europe Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 23 UK Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 24 UK Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 25 UK Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 26 Germany Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 27 Germany Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 28 Germany Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 29 France Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 30 France Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 31 France Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 32 Italy Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 33 Italy Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 34 Italy Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 35 Spain Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 36 Spain Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 37 Spain Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 38 Denmark Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 39 Denmark Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 40 Denmark Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 41 Norway Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 42 Norway Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 43 Norway Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 44 Sweden Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 45 Sweden Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 46 Sweden Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 51 Japan Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 52 Japan Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 53 Japan Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 54 China Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 55 China Antimicrobial Resistance Diagnostics market, by Pathogen 2018 - 2030 (USD Million)
  • Table 56 China Antimicrobial Resistance Diagnostics market, by End Use 2018 - 2030 (USD Million)
  • Table 57 India Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 58 India Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 59 India Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 60 Australia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 61 Australia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 62 Australia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 63 South Korea Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 64 South Korea Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 65 South Korea Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 66 Thailand Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 67 Thailand Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 68 Thailand Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 69 Latin America Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 71 Latin America Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 72 Latin America Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 73 Brazil Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 74 Brazil Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 75 Brazil Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 76 Argentina Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 77 Argentina Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 78 Argentina Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Antimicrobial Resistance Diagnostics market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 83 South Africa Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 84 South Africa Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 85 South Africa Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 89 UAE Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 90 UAE Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 91 UAE Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Antimicrobial Resistance Diagnostics market, by Technology, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Antimicrobial Resistance Diagnostics market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Antimicrobial Resistance Diagnostics market, by End Use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Antimicrobial Resistance Diagnostics market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Antimicrobial resistance diagnostics market, Technology outlook key takeaways, 2024 & 2030 (USD Million)
  • Fig. 12 Antimicrobial resistance diagnostics market: Pathogen movement analysis, 2024 & 2030 (USD Million)
  • Fig. 13 Antimicrobial resistance diagnostics market: end use movement analysis, 2024 & 2030 (USD Million)
  • Fig. 14 Microbiology Culture market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 Immunoassay market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 PCR market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 NGS market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Mass Spectrometry market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 Rapid & Point of Care market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Drug Resistant Streptococcus Pneumoniae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Drug Resistant Campylobacter market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Clostridium Difficile market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Methicillin Resistant Staphylococcus Aureus market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Drug Resistant Neisseria Gonorrhoeae market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Drug Resistant Salmonella market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Hospitals market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic Laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Pharmaceutical & Biotechnology Companies market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 North America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 US antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Europe antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 UK antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Germany antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 France antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Spain antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Italy antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Norway antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Denmark antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Sweden antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Asia Pacific antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 China antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Japan antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 India antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Korea antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Australia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Thailand antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Latin America antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Brazil antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Argentina antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Middle East and Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 South Africa antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Saudi Arabia antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 UAE antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Kuwait antimicrobial resistance diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 List of key emerging company's/Allergen disruptors/innovators
目次
Product Code: GVR-4-68039-990-4

Antimicrobial Resistance Diagnostics Market Growth & Trends:

The global antimicrobial resistance diagnostics market size is expected to reach USD 6.70 billion by 2030, registering a CAGR of 6.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increased risk of developing drug-resistant bacterial infections, especially in healthcare facilities, and increasing government & non-government bodies' efforts to combat the threat of AMR are the major factor contributing to market growth. In addition, various strategic initiatives undertaken by leading market players to manage antimicrobial resistance are also contributing to market expansion. For instance, in March 2021, bioMerieux and GIZ collaborated to support the Nigerian center for disease control to strengthen the fight against AMR.

The rising adoption of rapid testing and PoC tests for drug-resistant bacterial infections is anticipated to augment the market over the projected period. Moreover, leading market players such as Danaher, Abbott, and others have a robust product portfolio of rapid diagnostic tests for antimicrobial-resistant infections. Furthermore, the increasing involvement of non-government bodies such as AMR Industry Alliance is assisting regulatory bodies to make strategies to boost the development of diagnostic solutions to manage antimicrobial resistance.

Increasing funding for the development of novel and automated test solutions for the diagnosis of antimicrobial-resistant infections is anticipated to boost market growth over the forecast period. For instance, in May 2022, the European Investment Bank funded more than USD 24 million to POCARED Diagnostics for the R&D of fully automated testing of microbial diseases. POCARED Diagnostics is involved in the development of novel microbiology tests that can provide results within hours.

Antimicrobial resistance is expected to rise in the coming years. Hence, demand for accurate & fast testing options is expected to increase for the effective management and progression monitoring of antimicrobial resistance. According to the CDC, the annual direct healthcare expenditure of antimicrobial resistance is around USD 20 billion in the U.S. High cost of disease management is driving the demand for rapid tests for the diagnosis of infections at an early stage.

Key market players are continuously involved in the development of novel tests to strengthen their market position. Moreover, other strategies such as acquisitions, partnerships, and collaborations are also adopted by leading players to expand their product portfolio in different parts of the globe. For instance, in August 2022, Accelerate Diagnostics and BD announced a collaboration to combat the threat of antimicrobial resistance. As per the deal, BD will provide Accelerate Diagnostics rapid diagnostic solutions for antibiotics-associated resistance to its vast customers.

Antimicrobial Resistance Diagnostics Market Report Highlights:

  • The PCR segment dominated the market and accounted for the largest revenue share of 24.19% in 2024. Advancements in PCR technology, along with its widespread adoption due to its high accuracy, are key factors driving the significant share of this segment.
  • In 2024, the methicillin resistant staphylococcus aureus segment held the largest market share at 28.33%. The rising incidence of MRSA in hospital settings is a key driver for the expansion of this segment.
  • In 2024, the hospitals segment led the market, accounting for 48.07% of the revenue share. The growth of this segment is driven by several factors, including the rising incidence of hospital-acquired infections and increased hospitalizations due to antimicrobial-resistant (AMR) infections, which often lead to prolonged hospital stays.
  • North America antimicrobial resistance diagnostics market dominated the overall global market with a revenue share of 42.03% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Pathogen
    • 1.2.3. End Use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Antimicrobial Resistance Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increase in risk of developing drug - resistant bacterial infections
      • 3.2.1.2. Introduction of novel technologies to diagnose AMR infections
      • 3.2.1.3. Favorable government initiatives
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of stringent rules and regulations pertaining to diagnostics
  • 3.3. Antimicrobial Resistance Diagnostics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Antimicrobial Resistance Diagnostics Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Antimicrobial Resistance Diagnostics Market: Technology Movement Analysis
  • 4.3. Antimicrobial Resistance Diagnostics Market by Technology Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Microbiology Culture
    • 4.5.1. Microbiology Culture Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Immunoassay
    • 4.6.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.2. PCR
      • 4.6.2.1. PCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.3. NGS
      • 4.6.3.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.4. Mass Spectrometry
      • 4.6.4.1. Mass Spectrometry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.5. Rapid & Point of Care
      • 4.6.5.1. Rapid & Point of Care Assays Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Antimicrobial Resistance Diagnostics Market: Pathogen Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Antimicrobial Resistance Diagnostics Market: Pathogen Movement Analysis
  • 5.3. Antimicrobial Resistance Diagnostics Market by Pathogen Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Drug Resistant Streptococcus Pneumoniae (DRSP)
    • 5.5.1. Drug Resistant Streptococcus Pneumoniae (DRSP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Drug Resistant Campylobacter (DRC)
    • 5.6.1. Drug Resistant Campylobacter (DRC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Clostridium Difficile (CD)
    • 5.7.1. Clostridium Difficile (CD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Drug Resistant Neisseria Gonorrhoeae (DRNG)
    • 5.8.1. Drug Resistant Neisseria Gonorrhoeae (DRNG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Drug Resistant Salmonella (DRNTS)
    • 5.9.1. Drug Resistant Salmonella (DRNTS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Antimicrobial Resistance Diagnostics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Antimicrobial Resistance Diagnostics Market: End Use Movement Analysis
  • 6.3. Antimicrobial Resistance Diagnostics Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospitals
    • 6.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Pharmaceutical & Biotechnology Companies
    • 6.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Antimicrobial Resistance Diagnostics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. bioMerieux
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. F. Hoffmann - La Roche Ltd
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Abbott
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. BD
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Danaher
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Accelerate Diagnostics, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Molsid
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Vela Diagnostics
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Visby Medical, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Hologic, Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives